Showing 1921-1930 of 2165 results for "".
- Ocular Therapeutix Announces Board of Directors and Leadership Updateshttps://modernod.com/news/ocular-therapeutix-announces-board-of-directors-and-leadership-updates/2482128/Ocular Therapeutix announced Board of Directors and leadership updates with the addition of Pravin U. Dugel, MD as Executive Chairman; and the additions of Jeffrey S. Heier, MD, Peter K. Kaiser, MD, and Sanjay Nayak, MBBS, PhD, to the Ocular management
- Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Eye Care Divisionhttps://modernod.com/news/viatris-closes-acquisitions-of-oyster-point-pharma-and-famy-life-sciences-establishing-new-viatris-eye-care-division-1/2481326/Viatris announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. The transaction was first announced on November 7. Former Oyster Point Pharma CEO, Jeffrey Nau, PhD, MMS, will lead the new di
- Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successorhttps://modernod.com/news/spark-therapeutics-announces-departure-of-ceo-and-founder-jeff-marrazzo-coo-ron-philip-named-as-successor/2480664/Spark Therapeutics, a member of the Roche Group, announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey D. Marrazzo as chief executive officer. Mr. Marrazzo, who co-founded the company in 2013, will step down on April 1. “When I thin
- Regenxbio Announces Additional Positive Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd/2476995/Regenxbio announced interim data from the ongoing phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). The results were presented by Jeffrey S. Heier, MD, Co-President and Director of Retina Research at Ophthalmic Consultants
- Bausch + Lomb and Heidelberg Engineering Introduce SeeLuma Fully Digital Surgical Visualization Platformhttps://modernod.com/news/bausch-lomb-and-heidelberg-engineering-introduce-seeluma-fully-digital-surgical-visualization-platform/2481528/Bausch + Lomb and Heidelberg Engineering announced the introduction of the SeeLuma Fully Digital Surgical Visualization Platform, which is designed to p
- Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trialhttps://modernod.com/news/nicox-announces-last-patient-completes-the-ncx-470-denali-phase-3-clinical-trial/2482865/Nicox SA announced the completion of patient treatment and follow-up in the Denali phase 3 clinical trial for NCX 470, its lead candidate for the treatment of open-angle glaucoma and ocular hypertension. In total, 696 p
- iVeena Submits IND Application to the FDA for Phase 2 Clinical Trial for Pediatric Myopiahttps://modernod.com/news/iveena-submits-ind-application-to-the-fda-for-phase-2-clinical-trial-for-pediatric-myopia/2482830/iVeena Delivery Systems announced the submission of an investigational new drug (IND) application to the FDA for IVMED-85 for the treatment of pediatric myopia. IVMED-85 is a new chemical entity (NCE), p
- Glaukos Receives Permanent J-Code for iDose TRhttps://modernod.com/news/glaukos-receives-permanent-j-code-for-idose-tr/2482208/Glaukos announced that CMS has assigned a unique, permanent J-code (J7355) for iDose TR (travoprost intracameral implant) 75 mcg, a p
- Study: Lab-Grown ‘Mini-Corneas’ Mimic Developing Human Corneashttps://modernod.com/news/study-lab-grown-mini-corneas-mimic-developing-human-corneas/2481678/Researchers at NYU Langone Health say three-dimensional, lab-grown “mini-corneas” resemble the developing human cornea, potentially making them a new tool for the study of corneal diseases. P
- NIH: Eye Experts Weigh In on Artificial Tears in Midst of Infectious Outbreakhttps://modernod.com/news/nih-eye-experts-weigh-in-on-artificial-tears-in-midst-of-infectious-outbreak/2481452/The Centers for Disease Control and Prevention (CDC) is investigating how the virulent strain of P. aeruginosa ended up in EzriCare and Delsam Pharma artificial tears. According to an